Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis.

Author: BalbiManrico, BezanteGian Paolo, LantieriFrancesca, MurdacaGiuseppe, PuppoFrancesco

Paper Details 
Original Abstract of the Article :
OBJECTIVE: To investigate the effects of long-term treatment with bosentan on pulmonary arterial hypertension (PAH) in patients with systemic sclerosis. METHODS: Patients with systemic sclerosis were followed between 2003 and 2014; those who developed digital ulcers were treated with standard regim...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536521/

データ提供:米国国立医学図書館(NLM)

Bosentan for Systemic Sclerosis: A Protective Oasis in the Desert of PAH

Systemic sclerosis, a complex autoimmune disease, can lead to the development of pulmonary arterial hypertension (PAH), a condition that can be like a choking sandstorm in the lungs. This study, like a team of researchers seeking a cure in the vast desert of autoimmune disease, investigates the long-term effects of bosentan, an endothelin receptor antagonist, on the development of PAH in patients with systemic sclerosis. The researchers found that bosentan significantly reduced the risk of developing PAH in patients with systemic sclerosis, potentially offering a protective oasis in the desert of this challenging condition.

Bosentan: A Potential Shield Against PAH in Systemic Sclerosis

This research provides encouraging evidence for the use of bosentan as a preventative measure for PAH in patients with systemic sclerosis. The findings suggest that this medication could play a crucial role in managing this complex condition and improving outcomes for patients. It's a promising step forward in the fight against PAH.

Bosentan: A Guiding Star in the Desert of Systemic Sclerosis

Systemic sclerosis can be a challenging condition, but this study offers a glimmer of hope. The research highlights the potential of bosentan to protect patients from the debilitating consequences of PAH. It's a reminder that even in the vast desert of autoimmune disease, there are often oases of hope and possibility waiting to be discovered.

Dr.Camel's Conclusion

Bosentan is like a protective oasis in the vast desert of systemic sclerosis, offering a shield against the development of PAH. This research provides valuable insights into the potential for this medication to improve the lives of patients with this challenging condition. It's a reminder that even in the harshest medical landscapes, there are always new discoveries to be made.

Date :
  1. Date Completed n.d.
  2. Date Revised 2019-11-20
Further Info :

Pubmed ID

27683147

DOI: Digital Object Identifier

PMC5536521

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.